Bullboard - Stock Discussion Forum Forte Biosciences Inc FBRX

Healthcare Biotechnology

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The Company is advancing its product candidate, FB-102, which is a proprietary molecule with potentially broad autoimmune applications, including in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA). The Company’s FB-102 program... see more

Add To Watchlist

NDAQ:FBRX - Post Discussion

Forte Biosciences Inc > Forte Secures 53M Boost for Autoimmune Breakthroughs in 2025

View:

Post by MarketEngine17 on Nov 20, 2024 12:32pm

Forte Secures 53M Boost for Autoimmune Breakthroughs in 2025

With $53 million raised through an oversubscribed equity financing, Forte has secured support from major institutional investors such as OrbiMed and Janus Henderson. These funds will drive the advancement of FB102, their key candidate targeting autoimmune diseases. As the celiac disease trial progresses and new indications are planned, Forte looks set for significant breakthroughs in 2025.